Investing
Top 10 Analyst Upgrades & Downgrades (ATK, CELG, NTAP, NVLS, WMT, ATHN, ARNA, BK, GENZ, Q)
Published:
These are the top 10 analyst upgrades, downgrades, and initiations we have seen early this Monday morning:
Alliant Techsystems (ATK) Started as Buy at Jefferies.
Celgene (CELG) raised to Outperform at R.W.Baird.
NetApp (NTAP) raised to Conviction Buy List at Goldman Sachs
Novellus (NVLS) Raised to Outperform at Credit Suisse.
Wal-Mart (WMT) Started as Overweight at HSBC.
Athenahealth (ATHN) started as Sell at Citigroup.
Arena Pharmaceuticals (ARNA) cut to Market Perform at Leerink Swann.
Bank of New York Mellon (BK) Cut to Neutral at Goldman Sachs.
Genzyme (GENZ) Cut to Perform at Oppenheimer.
Qwest (Q) Cut to Conviction Sell List, but was already a Sell, at Goldman Sachs.
JON C. OGG
Credit Card Companies Are Doing Something Nuts
Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.
It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.
We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
